Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present interim data from its Phase 1b study at World Parkinson’s Congress and the GBA1 Meeting 2026, both ...
VQ-101 is the first small molecule to demonstrate > 75% activation of the lysosomal enzyme glucocerebrosidase (GCase) in humans In healthy volunteers, VQ-101 was well tolerated and achieved peripheral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results